BeyondSpring Stock Rockets 250% As Cancer Drug Tops Chemotherapy

BeyondSpring (BYSI) said Wednesday a regimen containing its cancer drug outperformed chemotherapy alone in lung cancer patients, and BYSI stock more than tripled to a record high.


The company tested a regimen containing its drug, plinabulin, against chemotherapy in patients with a form of lung cancer. The regimen increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with chemo.

Now, BeyondSpring says it’s preparing to ask for plinabulin approval in the U.S. and China. The results also set the stage for plinabulin to be used in combination with immuno-oncology drugs, widening its potential use down the road.

In premarket trading on the stock market today, BYSI stock rocketed 247.3%, trading near 33.40. Shares closed below 10 on Tuesday.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Amgen Stock Dips On Guidance Trim Despite Second-Quarter Beat

Eli Lilly Stock Hits A Record High As Alzheimer’s Enthusiasm Grows

Find The Best Long-Term Investments With IBD Long-Term Leaders

Get Timely Buy & Sell Alerts With IBD Leaderboard

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

Most Related Links :
dutifulnews Governmental News Finance News

Source link

Back to top button